alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › randomized-controlled-trial

randomized-controlled-trial

9 studies tagged randomized-controlled-trial, dated 2016-07-19 to 2024-09-11. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Acute exercise alters brain glucose metabolism in aging and Alzheimer's disease 2024-09-11
  2. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease 2024-07-05
  3. Multi-night acoustic stimulation is associated with better sleep, amyloid dynamics, and memory in older adults with cognitive impairment 2024-05-14

Studies

9 studies carry this tag.

Date range

2016 to 2024

Top journals

  • GeroScience 2
  • Alzheimer's research & therapy 1
  • BMC complementary medicine and therapies 1
  • BMJ open 1
  • Frontiers in psychology 1

8 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Acute exercise alters brain glucose metabolism in aging and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. The Journal of physiology 2024-09-11 Biomarkers

    There is evidence that aerobic exercise improves brain health.

  2. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 80 out of 100. Alzheimer's research & therapy 2024-07-05 Biomarkers

    From June 2017 to December 2021, 19 participants were enrolled, randomized within dose cohorts (5 active: 3 placebo) of 60 mg once/day and 60 mg twice/day; 1 participant was enrolled and completed 60 mg three times/day. 10 active drug and 5 placebo participants completed all study procedures.

  3. Multi-night acoustic stimulation is associated with better sleep, amyloid dynamics, and memory in older adults with cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. GeroScience 2024-05-14 Biomarkers

    Sleep is a potential early, modifiable risk factor for cognitive decline and dementia.

  4. The impact of exercise on blood-based biomarkers of Alzheimer's disease in cognitively unimpaired older adults

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. GeroScience 2024-03-15 Biomarkers

    Physical activity is a promising preventative strategy for Alzheimer's disease: it is associated with lower dementia risk, better cognition, greater brain volume and lower brain beta-amyloid.

  5. Comparing the effects of olfactory-based sensory stimulation and board game training on cognition, emotion, and blood biomarkers among individuals with dementia: A pilot randomized controlled trial

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Frontiers in psychology 2022-09-20 Biomarkers

    Olfactory dysfunction can indicate early cognitive decline and is associated with dementia symptoms.

  6. Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. BMC complementary medicine and therapies 2021-10-07 Biomarkers

    KGT may provide a safe and effective treatment option for patients with aMCI.

  7. Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial

    ✓ Peer-reviewed alzhub usefulness score 84 out of 100. JAMA network open 2021-09-01 Biomarkers

    In a cross-sectional analysis of 26 individuals, bifrontal cortical FDG hypometabolism was associated with worse Clinical Dementia Rating (CDR) plus National Alzheimer's Coordinating Center frontotemporal lobar degeneration sum of boxes score (b = -3.6 × 10-2 standardized uptake value ratio [SUVR] units/CDR units; 95% CI, -4.9 × 10-2 to -2.2 × 10-2; P < .001), high cerebrospinal fluid NfL (b = -9.2 × 10-5 SUVR units/pg NfL/mL; 95% CI, -1.3 × 10-4 to -5.6 × 10-5; P < .001), and high CSF t-tau (-7.2 × 10-4 SUVR units/pg t-tau/mL; 95% CI, -1.4 × 10-3 to -9.5 × 10-5; P = .03).

  8. Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Sleep 2018-05-01 Biomarkers

    Study objectives To investigate the cumulative effect of five consecutive nights of partial sleep deprivation (PSD) on a panel of cerebrospinal fluid (CSF) biomarkers in healthy adults.

  9. European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. BMJ open 2016-07-19 Biomarkers

    In conjunction with the NILVAD trial, a European Multicentre Double-Blind Placebo Controlled trial of Nilvadipine in Mild-to-Moderate Alzheimer's disease (AD), there are four NILVAD substudies in which eligible NILVAD patients are also invited to participate.

All topic tags with their study counts